Cannara BiotechLOVFF +5.52%83 PB Ratio is 1.36 as of Jun. 29, 2026, which is 11% below its 10-year median of 1.52. GuruFocus rates LOVFF with a GF Score™ of 83/100 and a GF Value™ of $1.15 (Fairly Valued). The stock has 4 warning signs investors should review. Among 922 Drug Manufacturers companies, Cannara Biotech ranks better than 63.45% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-06-29), Cannara Biotech's share price is $1.2135. Cannara Biotech's Book Value per Share for the quarter that ended in Feb. 2026 was $0.89. Hence, Cannara Biotech's PB Ratio of today is 1.36.
Good Sign:
Cannara Biotech Inc stock PB Ratio (=1.38) is close to 1-year low of 1.36.
The historical rank and industry rank for Cannara Biotech's PB Ratio or its related term are showing as below:
LOVFF'
s PB Ratio Range Over the Past 10 Years
Min: 0.62 Med: 1.52 Max: 3.66
Current: 1.44
During the past 8 years, Cannara Biotech's highest PB Ratio was 3.66. The lowest was 0.62. And the median was 1.52.
LOVFF's PB Ratio is ranked better than 63.45% of 922
companies
in the Drug Manufacturers industry
Industry Median: 1.845
vs LOVFF: 1.44
During the past 12 months, Cannara Biotech's average Book Value Per Share Growth Rate was 18.20% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 13.70% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 14.80% per year.
During the past 8 years, the highest 3-Year average Book Value Per Share Growth Rate of Cannara Biotech was 51.10% per year. The lowest was 4.50% per year. And the median was 13.70% per year.
Back to Basics: PB Ratio
Cannara Biotech (OTCPK:LOVFF) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Cannara Biotech PB Ratio Related Terms
Cannara Biotech PB Ratio Historical Data
* Premium members only.
The historical data trend for Cannara Biotech's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Cannara Biotech's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cannara Biotech PB Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Cannara Biotech's PB Ratio distribution charts can be found below:
* The bar in red indicates where Cannara Biotech's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
Cannara Biotech's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Cannara Biotech (LOVFF) has a PB Ratio of 1.36 as of Jun. 29, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Cannara Biotech and its competitors. This is 11% below median its historical median of 1.52. Over the past decade, Cannara Biotech's PB Ratio has ranged from 0.62 to 3.66. According to the industry distribution chart, Cannara Biotech ranks #337 out of 922 companies in the Drug Manufacturers industry, placing it in the top 36.6%.
Is Cannara Biotech's PB Ratio too high?
Cannara Biotech's current PB Ratio of 1.36 is 11% below median its 10-year median of 1.52. Over the past 10 years, this metric has ranged from a low of 0.62 to a high of 3.66. The Drug Manufacturers industry median PB Ratio is 1.85. Cannara Biotech's value of 1.36 is 26.3% below this industry median. Based on the distribution chart, Cannara Biotech ranks #337 out of 922 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Cannara Biotech has a GF Score™ of 83/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Cannara Biotech's PB Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Cannara Biotech ranks #337 out of 922 companies for PB Ratio. This puts Cannara Biotech in the upper half of its industry. The industry median PB Ratio is 1.85. Cannara Biotech's value of 1.36 is 26.3% below this benchmark. Historically, Cannara Biotech's own PB Ratio has ranged from 0.62 to 3.66 over the past decade. While the company's 10-year median is 1.52 vs. the industry median of 1.85, Cannara Biotech has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Drug Manufacturers company?
The median PB Ratio among Drug Manufacturers companies is 1.85, based on 922 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cannara Biotech's current PB Ratio of 1.36 is 26.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Cannara Biotech and its competitors. For the Drug Manufacturers industry, the median PB Ratio is 1.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cannara Biotech's current PB Ratio is 1.36, which is 11% below median its own 10-year median of 1.52. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cannara Biotech stock overvalued right now?
Based on GuruFocus' analysis, Cannara Biotech (LOVFF) is currently considered Fairly Valued. The stock's GF Value™ is $1.15, compared to a current price of $1.21 — trading 5.5% above its estimated fair value. The current PB Ratio is 1.36, which is 11% below median its 10-year median of 1.52 and 26.3% below the Drug Manufacturers industry median of 1.85. Cannara Biotech's overall GF Score™ is 83/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Cannara Biotech (LOVFF), the current PB Ratio is 1.36 as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cannara Biotech (LOVFF) Overvalued in 2026?
Based on GuruFocus' analysis, Cannara Biotech stock appears to be overvalued.
The current stock price of $1.21 is trading 5.5% above its estimated GF Value™ of $1.15.
GuruFocus considers Cannara Biotech to be Fairly Valued.
Key valuation signals for LOVFF:
PB Ratio: 1.36 (11% below median its 10-year median of 1.52)
GF Value™: $1.15 vs. price of $1.21 (5.5% above fair value)
Industry Position: 26.3% below the Drug Manufacturers median (#337 of 922)
No single metric tells the full story. See the LOVFF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cannara Biotech Inc is a vertically integrated producer of premium-grade cannabis and cannabis-derivative products for Canadian markets. The company owns two mega Quebec-based facilities. The company operates in in two segments; Indoor cannabis operations segment which includes the cultivation, processing and sale of dried cannabis and cannabis derivatives for the Canadian market and the Real estate operations segment related to the Farnham and Valleyfield building. Majority of the revenue for the company is generated from its Cannabis operations segment. .
83GF Score
Get the complete analysis for LOVFF
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LOVFF has been successfully added to your 
